Group B adenovirus encoding an anti-TCR-complex antibody or fragment
The present disclosure relates to a replication deficient oncolytic viral vector or replication capable group B oncolytic adenovirus selected from the group consisting of Ad11 and enadenotucirev, wherein the virus encodes an antibody or a binding fragment thereof for expression on the surface of a c...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
30.04.2024
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present disclosure relates to a replication deficient oncolytic viral vector or replication capable group B oncolytic adenovirus selected from the group consisting of Ad11 and enadenotucirev, wherein the virus encodes an antibody or a binding fragment thereof for expression on the surface of a cancer cell, wherein said antibody or binding fragment is specific to a CD3 protein of a T-cell receptor complex (TCR), wherein the virus does not encode a B7 protein or an active fragment thereof, pharmaceutical compositions comprising the same, and use of any one of the same in treatment, particularly in the treatment of cancer. |
---|---|
Bibliography: | Application Number: US201616062036 |